Serum Institute of India & Merck & Co.

Serum Institute of India: The Serum Institute of India is manufacturing a vaccine candidate developed by the University of Oxford, receiving up to $8.6 million from CEPI for its development.

Merck & Co.: Merck & Co.'s approved vaccine Ervebo for the Zaire strain of Ebola is referenced as a technological precedent for IAVI's Bundibugyo vaccine candidate.

Serum Institute of India: The Serum Institute of India collaborated with the University of Oxford to develop ChAdOx1 Bundibugyo, a vaccine candidate for the Ebola Bundibugyo strain.

Merck & Co.: Merck & Co. developed Ervebo, the only licensed Ebola vaccine, which the World Health Organization reviewed but recommended against deploying outside research settings for the Bundibugyo strain due to limited evidence.

Serum Institute of India: The Serum Institute of India is manufacturing doses of a vaccine candidate built on the University of Oxford/AstraZeneca platform, which could be used for clinical trials against the Bundibugyo ebolavirus.

Merck & Co.: Merck & Co.>>>'s Ervebo vaccine, effective against the Zaire strain of Ebola, is being considered for potential use against the Uganda — Bundibugyo strain, though its efficacy is still under assessment.